Cambrex Expands Process Research and Development Capabilities Across North America

EAST RUTHERFORD, N.J., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced an investment to expand chemical and analytical development capabilities at its Charles City, Iowa plant. The project forms part of the company’s strategic plan to increase its development capacity and resources in North America.

The expansion will see the construction of an additional 2,000 sq.ft. of laboratory space for development projects, and will support the hiring of an additional 14 chemists. The building, installation and validation of equipment is expected to be completed by Q1 2018.

The expansion at Charles City is in parallel to the investments announced in 2017 at Cambrex’s facility in High Point, North Carolina, where a new 11,000 sq.ft. analytical laboratory and 400 sq.ft. pilot plant with a total reactor capacity of 4,000 liters are currently being completed. These expansions at High Point will create up to 18 new jobs.

“The Charles City site has seen multiple investments and expansions in manufacturing capacity over the past five years to meet market demand, and this in turn, has led to us needing to increase the capacity of the supporting development and analytical functions,” commented Joe Nettleton, Vice President US Operations, Cambrex. “Our strategy in expanding the development capabilities across the sites at both Charles City and High Point is to ensure both facilities are harmonized and can function synergistically so that projects can be seamlessly transferred between the two.”

Cambrex’s Charles City, Iowa facility is located on a 45-acre site and manufactures a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances. The High Point site, formerly PharmaCore, Inc., was acquired by Cambrex in October 2016, and produces complex APIs and intermediates in batch sizes from milligrams to 100kg to support clinical trials from Phase I to Phase III.

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances.  For more information, please visit

Alex Maw
Director, Marketing and Communications
Tel: +44 7803 443 155